Stock listing

NASDAQ:SGMT Sagimet Biosciences Inc. - Series A Stock

Home listing (NASDAQ) of Sagimet Biosciences Inc. - Series A

Follow Sagimet Biosciences Inc. - Series A into a list and get an email when it puts out news.

Share price · NASDAQ:SGMT

$9.08 USD -1.03 (-10.2%)

Close on Nov 20, 2026

Past year +24.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$8.83 – $9.40 USDNov 20, 2026
Volume
1.50M sharesNov 20, 2026
Market cap
$638.7M USDAt the close on Nov 20, 2026 · price × 70.34M shares outstanding
52-week range
$4.50 – $11.45 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$12.17M USDMedian day 1.09M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Sagimet Biosciences Inc. - Series A logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:SGMT · Home$9.08 USD-1.03 (-10.2%)1,500,685$9.32$9.40$8.832$10.11Close on Nov 20, 2026
Frankfurt:0O2€8.50 EUR-0.48 (-5.3%)—€8.60€8.62€8.50€8.98Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SGMT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$9.08-1.03-10.2%$9.32$9.40$8.8321,500,685
$10.11+0.26+2.6%$9.86$10.27$9.81932,587
$9.85-0.28-2.8%$10.09$10.20$9.64843,298
$10.13-0.09-0.9%$10.10$10.46$9.911,023,998
$10.22-0.71-6.5%$10.84$10.84$9.96759,442
$10.93-0.48-4.2%$11.11$11.31$10.811,440,961
$11.41+0.52+4.8%$10.93$11.44$10.801,790,259
$10.89+0.06+0.6%$10.66$11.00$10.481,573,139
$10.83+0.98+9.9%$10.01$10.86$9.701,093,246
$9.85+0.73+8.0%$9.25$9.87$9.02857,846
$9.12-0.87-8.7%$9.83$9.95$9.0551,153,760
$9.99+0.04+0.4%$10.25$10.43$9.64755,914
$9.95+0.26+2.7%$9.80$10.16$9.659636,837
$9.69-0.23-2.3%$9.92$9.97$9.615735,883
$9.92-0.51-4.9%$10.41$10.54$9.82989,119
$10.43-0.31-2.9%$10.82$10.92$10.27738,502
$10.74+0.32+3.1%$10.32$10.76$10.261,235,069
$10.42+0.86+9.0%$9.58$10.48$9.551,108,685
$9.56-0.02-0.2%$9.61$9.70$9.41767,181
$9.58-0.37-3.7%$9.95$9.95$9.495694,900
$9.95-0.04-0.4%$10.00$10.15$9.6281,006,600
$9.99+0.25+2.6%$9.76$10.21$9.721,578,100
$9.74+0.88+9.9%$8.88$10.15$8.832,175,500
$8.86+0.84+10.5%$8.24$9.005$8.151,684,000
$8.02-0.15-1.8%$8.15$8.25$7.941,088,900
$8.17+0.625+8.3%$7.61$8.275$7.541,367,000
$7.545-0.435-5.5%$7.78$8.00$7.511,984,800
$7.98-0.82-9.3%$8.70$8.74$7.882,349,300
$8.80-0.13-1.5%$8.85$9.145$8.7351,156,400
$8.93+0.01+0.1%$8.84$9.05$8.78763,500
$8.92+0.04+0.5%$8.80$8.94$8.631,229,000
$8.88+0.12+1.4%$8.65$8.97$8.598631,600
$8.76-0.27-3.0%$8.99$8.99$8.55896,300
$9.03-0.11-1.2%$9.075$9.12$8.401,528,700
$9.14-0.23-2.5%$9.26$9.38$8.881,712,500
$9.37-0.51-5.2%$9.63$10.01$9.3152,008,400
$9.88+0.55+5.9%$10.61$10.93$9.465,453,100
$9.33-0.61-6.1%$9.92$9.92$9.25856,800
$9.94+0.70+7.6%$9.15$9.95$9.0251,345,800
$9.24+0.13+1.4%$9.11$9.265$8.891,246,500
$9.11-1.31-12.6%$9.78$9.99$8.6853,722,700
$10.42-0.67-6.0%$11.23$11.26$10.151,115,900
$11.09+0.29+2.7%$10.84$11.33$10.72874,100
$10.80-0.29-2.6%$11.20$11.21$10.66753,300
$11.09-0.08-0.7%$11.17$11.40$10.801,854,000
$11.17+0.71+6.8%$10.69$11.34$10.681,019,100
$10.460.000.0%$10.51$10.62$10.25620,600
$10.46-0.42-3.9%$10.81$10.84$10.31852,700
$10.880.000.0%$10.96$11.10$10.82516,700
$10.88-0.18-1.6%$11.33$11.35$10.77639,400
$11.06+0.20+1.8%$10.75$11.45$10.67937,700
$10.86+0.15+1.4%$11.25$11.27$10.691,249,900
$10.71-0.23-2.1%$10.84$11.17$10.65805,400
$10.94+0.02+0.2%$10.79$10.98$10.531,250,100
$10.92-0.07-0.6%$11.21$11.24$10.621,142,100
$10.99+0.49+4.7%$10.51$11.06$10.511,798,000
$10.50+0.24+2.3%$10.15$10.72$10.15752,200
$10.26-0.29-2.7%$10.36$10.44$10.21688,400
$10.55-0.20-1.9%$10.62$10.81$10.47574,000
$10.75-0.11-1.0%$10.90$10.95$10.54657,600
$10.86+0.57+5.5%$10.26$10.87$10.111,236,700
$10.29+0.08+0.8%$10.38$10.60$10.20968,555
$10.21-0.04-0.4%$10.13$10.51$9.951,242,184
$10.25+0.07+0.7%$10.22$10.48$10.061,022,300
$10.18-0.40-3.8%$10.48$10.64$10.151,138,700
Ticker
NASDAQ:SGMT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Sagimet Biosciences Inc. - Series A news

Sagimet Biosciences Inc. - Series A on 6ix

Sector
Health care
Industry
Biotechnology
News releases
33 in the last 12 months · 91 in all · newest Nov 12, 2026 · oldest 2023
Decks
34 decks · latest Nov 12, 2026

Where Sagimet Biosciences Inc. - Series A is listed

ListingExchangeCountryCurrency
NASDAQ:SGMT · Home listing · This pageNASDAQUnited StatesUSD
gettex:0O2gettexGermanyEUR
BOATS:SGMTBOATSUnited StatesUSD
Lang & Schwarz:A3CPAMLang & SchwarzGermanyEUR
LS Exchange:A3CPAMLS ExchangeGermanyEUR
Munich:0O2MunichGermanyEUR
Dusseldorf:0O2DusseldorfGermanyEUR
Tradegate:0O2TradegateGermanyEUR
Frankfurt:0O2FrankfurtGermanyEUR
Stuttgart:0O2StuttgartGermanyEUR

Valuation

Price/book 2.6× against a median of 4.3×: 4th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$404.3M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
2.6×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.96

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Sagimet Biosciences Inc. - Series A · NASDAQ:SGMTUS$638.7MUS$404.3Mn/an/an/a2.6×n/a0.0×1.96
Sun Pharma Advanced Research Co. Ltd. · NSE:SPARCUS$666.0MUS$519.1M3.8×2.5×2.9×4.3×84.7%0.0×n/a
Oscotec Inc. · KRX:039200US$660.8MUS$660.8M11.6×6.3×n/a4.5×54.0%0.0×n/a
Shouyao Holdings Beijing Co. Ltd. Class A · SSE:688197US$648.7MUS$566.3Mn/a37.8×n/a6.8×−18.6%0.0×n/a
Prime Medicine, Inc. · NASDAQ:PRMEUS$645.8MUS$695.1Mn/a98.4×n/a76.5×n/a13.1×2.28
Gubra A/S · OMXCOP:GUBRAUS$638.5MUS$533.6M2.6×1.4×1.7×4.2×64.1%0.2×n/a
Kura Oncology, Inc. · NASDAQ:KURAUS$634.9MUS$152.6Mn/a1.9×n/a35.4×−369.3%0.6×1.30
Alphamab Oncology · HKEX:9966US$628.9MUS$454.4Mn/a5.5×n/a2.5×−20.1%0.2×n/a
Iambic Therapeutics, Inc. · NASDAQ:IAMUS$621.4MUS$369.4Mn/a39.2×n/an/a−820.0%n/an/a
Janux Therapeutics, Inc. · NASDAQ:JANXUS$616.7M−US$308.6Mn/a−13.3×n/a0.7×−428.7%0.0×0.95
Olema Pharmaceuticals, Inc. · NASDAQ:OLMAUS$615.0MUS$204.6Mn/an/an/a1.7×n/a0.0×1.25
Median of the othersUS$636.7MUS$486.7M3.8×5.5×2.3×4.3×−19.4%0.0×1.27

Forecasts

9 strong buy · 2 buy · 1 strong sell · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
27.27 USD · Analysts' mean
EPS, year to Dec 2026
-1.25 · 7 analysts

Team and board

Officers

OfficerRole
David HappelChief Executive Officer & Director
Thierry ChaucheChief Financial Officer
Elizabeth RozekChief Legal & Administrative Officer
Robert D’UrsoSenior Vice President of New Products
Andreas GrauerChief Medical Officer
Marie O’FarrellChief Scientific Officer

Board

DirectorRole
George KembleChair
Anne PhillipsBoard Member
Beth SeidenbergLead Independent Director
David HappelChief Executive Officer & Director
Elizabeth GrammerBoard Member
Jennifer JarrettBoard Member
Paul HoelscherBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−4.2%
Q2 2026Aug 11, 2026 · Before open−0.5%
Q1 2026May 12, 2026 · Before open−0.5%
Q4 2025Mar 11, 2026−3.4%
Q3 2025Nov 13, 2025 · Before open−12.2%
Q2 2025Aug 13, 2025 · Before open+0.3%
Q1 2025May 8, 2025−2.4%
Q4 2024Mar 12, 2025 · Before open+3.4%
Q3 2024Nov 14, 2024 · Before open−13.9%
Q2 2024Aug 14, 2024 · Before open−7.1%
All 15 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · Before open+5.5%
Q4 2023Mar 25, 2024 · Before open+15.7%
Q3 2023Nov 13, 2023 · Before open−13.7%
Q2 2023Aug 21, 2023 · After close−13.7%
Q1 2023May 31, 2023

Open Events

Decks

DeckKindSlidesDate
Sagimet Biosciences — Investor Presentation (November 2026)Investor deck33 slidesNov 12, 2026
Sagimet Biosciences — Investor Presentation (October 2026)Investor deck31 slidesOct 22, 2026
Sagimet Biosciences — Investor Presentation (September 2026)Investor deck30 slidesSeptember 2026
Sagimet Biosciences — Corporate Update (August 2026)Corporate update22 slidesAug 11, 2026
Sagimet Biosciences — Investor Presentation (July 2026)Investor deck22 slidesJul 21, 2026
Sagimet Biosciences — Corporate Update (April 2026)Corporate update22 slidesApr 30, 2026
Sagimet Biosciences — Investor Presentation (April 2026)Investor deck22 slidesApr 27, 2026
Sagimet Biosciences — Technical Presentation (April 2026)Technical17 slidesApr 15, 2026
Sagimet Biosciences — Corporate Update (March 2026)Corporate update52 slidesMar 11, 2026
Sagimet Biosciences — Investor Presentation (February 2026)Investor deck52 slidesFeb 2, 2026
All 34 decks
DeckKindSlidesDate
Sagimet Biosciences — Investor Presentation (December 2025)Investor deck51 slidesDec 18, 2025
Sagimet Biosciences — Investor Presentation (November 2025)Investor deck51 slidesNov 13, 2025
Sagimet Biosciences — Investor Presentation (October 2025)Investor deck51 slidesOct 23, 2025
Sagimet Biosciences — Investor Presentation (August 2025)Investor deck50 slidesAug 13, 2025
Sagimet Biosciences — Investor Presentation (May 2025)Investor deck39 slidesMay 8, 2025
Sagimet Biosciences — Corporate Update (March 2025)Corporate update36 slidesMar 12, 2025
Sagimet Biosciences — 2025 Keystone MASH symposiumConference18 slidesMarch 2025
Sagimet Biosciences — Investor Presentation (February 2025)Investor deck36 slidesFeb 14, 2025
Sagimet Biosciences — Investor Presentation (January 2025)Investor deck36 slidesJan 2, 2025
Sagimet Biosciences — Technical Presentation (January 2025)Technical20 slidesJanuary 2025
Sagimet Biosciences — Corporate Update (August 2024)Corporate update34 slidesAug 14, 2024
Sagimet Biosciences — Investor Presentation (July 2024)Investor deck34 slidesJul 2, 2024
Sagimet Biosciences — Investor Presentation (May 2024)Investor deck33 slidesMay 23, 2024
Sagimet Biosciences — Investor Presentation (March 2024)Investor deck33 slidesMar 25, 2024
Sagimet Biosciences — Corporate Update (January 2024)Corporate update18 slidesJan 22, 2024
Sagimet Biosciences — Investor Presentation (January 2024)Investor deck32 slidesJan 22, 2024
Sagimet Biosciences — Investor Presentation (December 2023)Investor deck30 slidesDec 29, 2023
Sagimet Biosciences — Investor Presentation (October 2023)Investor deck30 slidesOct 23, 2023
Sagimet Biosciences — Investor Presentation (August 2023)Investor deck30 slidesAug 10, 2023
Sagimet Biosciences — Technical Presentation (June 2023)Technical16 slidesJun 23, 2023
Sagimet Biosciences — Technical Presentation (March 2016)Technical21 slidesMarch 2016
Sagimet Biosciences — Technical Presentation (February 2016)Technical13 slidesFeb 24, 2016
Sagimet Biosciences — Technical Presentation (November 2014)Technical22 slidesNovember 2014
Sagimet Biosciences — Technical Presentation (November 2012)Technical12 slidesNov 11, 2012

Open Decks

IPO

Priced at US$16.00 a share on Jul 13, 2023.

Price
US$16.00 a share
Shares offered
5,312,500 shares of common stock
Offering size
US$85 million
Underwriters' option
Up to 796,875 more shares
Listing
SGMT on the Nasdaq Global Market
Underwriters
Goldman Sachs & Co. LLC, TD Cowen, Piper Sandler, JMP Securities · In the order on the cover
Shares delivered
On or about Jul 18, 2023

Steps

StepWhen
Draft sent to the SEC in confidenceMar 24, 2023
Filed publiclyJun 23, 2023
Amended twiceNewest Jul 10, 2023
Shares registered with an exchangeJul 11, 2023
Declared effective by the SECJul 13, 2023
Final prospectus, with the priceJul 17, 2023

Open IPO · From the cover of the final prospectus (424B4) filed Jul 17, 2023

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue002.00M0000
Cost of revenue130.0K134.0K124.0K88.0K
Gross profit2.00M-130.0K-134.0K-124.0K-88.0K
Research and development39.1M38.4M19.8M24.9M19.3M8.18M8.39M
Selling, general and administrative17.8M16.0M13.0M6.14M4.38M3.22M5.86M
Operating income-56.9M-54.5M-30.7M-31.1M-23.7M-11.4M-14.2M
Depreciation and amortization30.7M130.0K134.0K124.0K1.00K
EBITDA0-30.9M-23.6M-11.3M-14.2M
Interest expense064.0K
Income before tax-51.0M-45.6M-27.9M-30.5M-24.4M-11.4M-14.3M
Income tax00-2.86M-31.6M-23.7M-176.3K-9.00K
Net income-51.0M-45.6M-27.9M-30.5M-24.4M-11.4M-14.3M
Earnings per share, basic-1.58-1.45-2.66-165.20-1.10-0.51-0.64
Earnings per share, diluted-1.58-1.45-2.66-165.20

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents35.0M75.8M75.1M158.0K56.7M68.7M10.2M
Short-term investments78.1M75.4M19.8M32.2M0
Current assets116.4M152.8M96.6M32.8M58.7M68.7M10.8M
Property, plant and equipment194.0K318.0K
Total assets116.5M160.3M96.7M33.0M59.0M69.0M11.2M
Accounts payable1.31M1.43M186.0K1.13M761.0K513.0K1.20M
Current liabilities5.10M4.45M5.65M5.28M2.44M1.91M2.08M
Total debt78.0K78.0K65.0K211.0K348.0K210.0K341.0K
Total liabilities5.10M4.45M5.65M5.36M217.3M204.9M136.5M
Shareholders' equity111.4M155.8M91.1M-186.9M-158.3M-135.9M-125.3M
Shares outstanding32.3M31.4M0185.1K22.2M22.2M22.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-45.6M-42.4M-23.8M-24.5M-21.7M-10.4M-10.6M
Capital spending0000000
Free cash flow-45.6M-42.4M-23.8M-24.5M-21.7M-10.4M-10.6M
Cash from investing4.56M-61.7M12.6M-32.0M20.0K-27.0K
Cash from financing275.0K104.8M86.2M-73.0K9.74M68.9M18.5M
Change in cash1.60M-11.1M1.88M101.7M-12.0M58.5M7.91M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2026Big-stake noticeSEC
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportOct 22, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeOct 7, 2026Big-stake noticeSEC
8-K · Current reportSep 30, 2026Material contractSEC
424B5 · ProspectusSep 30, 2026Offer documentSEC
8-K · Current reportSep 30, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
424B3 · ProspectusSep 30, 2026Offer documentSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
144 · Notice of proposed saleAug 14, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
8-K · Current reportAug 13, 2026Current reportSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
144 · Notice of proposed saleAug 11, 2026Other filingsSEC
8-K · Current reportAug 11, 2026ResultsSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeJul 30, 2026Big-stake noticeSEC
4 · Change in ownershipJul 22, 2026Insider tradeSEC
4 · Change in ownershipJul 22, 2026Insider tradeSEC
4 · Change in ownershipJul 22, 2026Insider tradeSEC
8-K · Current reportJul 20, 2026Current reportSEC
144 · Notice of proposed saleJul 20, 2026Other filingsSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
8-K · Current reportJun 12, 2026Management or board changeSEC
8-K · Current reportJun 3, 2026Management or board changeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 14, 2026Insider tradeSEC
8-K · Current reportMay 12, 2026ResultsSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportApr 28, 2026Material contractSEC
424B5 · ProspectusApr 28, 2026Offer documentSEC
8-K · Current reportApr 27, 2026Current reportSEC
8-K · Current reportApr 27, 2026ResultsSEC
ARS · Annual report to shareholdersApr 21, 2026Annual reportSEC
DEF 14A · Proxy statementApr 21, 2026Meeting noticeSEC
8-K · Current reportApr 21, 2026Management or board changeSEC
S-8 · Registration statement for employee plansMar 11, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 11, 2026Offer documentSEC
8-K · Current reportMar 11, 2026ResultsSEC
10-K · Annual reportMar 11, 2026Annual reportSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
8-K · Current reportFeb 2, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 18, 2025Big-stake noticeSEC
8-K · Current reportDec 18, 2025Current reportSEC
8-K · Current reportDec 17, 2025Current reportSEC
4 · Change in ownershipNov 21, 2025Insider tradeSEC
144 · Notice of proposed saleNov 20, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 13, 2025ResultsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
8-K · Current reportOct 23, 2025Current reportSEC
8-K · Current reportAug 22, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
8-K · Current reportAug 14, 2025Material contractSEC
424B5 · ProspectusAug 14, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
8-K · Current reportAug 13, 2025ResultsSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
4 · Change in ownershipJul 23, 2025Insider tradeSEC
4 · Change in ownershipJul 23, 2025Insider tradeSEC
4 · Change in ownershipJul 23, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 24, 2025Big-stake noticeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
8-K · Current reportJun 10, 2025Management or board changeSEC
8-K · Current reportJun 4, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 20, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2025Big-stake noticeSEC
8-K · Current reportMay 8, 2025ResultsSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
UPLOAD · Letter from the SECMay 7, 2025Other filingsSEC
CORRESP · Letter to the SECMay 5, 2025Other filingsSEC
8-K · Current reportApr 30, 2025Management or board changeSEC
ARS · Annual report to shareholdersApr 30, 2025Annual reportSEC
DEF 14A · Proxy statementApr 30, 2025Meeting noticeSEC
UPLOAD · Letter from the SECApr 22, 2025Other filingsSEC
S-8 · Registration statement for employee plansMar 12, 2025Offer documentSEC
S-8 · Registration statement for employee plansMar 12, 2025Offer documentSEC
8-K · Current reportMar 12, 2025ResultsSEC
10-K · Annual reportMar 12, 2025Annual reportSEC
8-K · Current reportMar 11, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
8-K · Current reportFeb 14, 2025Current reportSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
8-K · Current reportJan 2, 2025Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
8-K · Current reportNov 14, 2024ResultsSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
EFFECT · Notice that a registration is effectiveAug 27, 2024Other filingsSEC
CORRESP · Letter to the SECAug 22, 2024Other filingsSEC
UPLOAD · Letter from the SECAug 19, 2024Other filingsSEC
8-K · Current reportAug 16, 2024Material contractSEC
S-3 · Registration statementAug 15, 2024Offer documentSEC
8-K · Current reportAug 14, 2024ResultsSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 5, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 5, 2024Insider tradeSEC
8-K · Current reportAug 1, 2024Management or board changeSEC
4 · Change in ownershipJul 25, 2024Insider tradeSEC
144 · Notice of proposed saleJul 23, 2024Other filingsSEC
4 · Change in ownershipJul 23, 2024Insider tradeSEC
4 · Change in ownershipJul 23, 2024Insider tradeSEC
4 · Change in ownershipJul 23, 2024Insider tradeSEC
8-K · Current reportJul 2, 2024Current reportSEC
8-K/A · Current report, amendedJun 13, 2024Current reportSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
8-K · Current reportJun 6, 2024Meeting outcomeSEC
8-K · Current reportMay 23, 2024Current reportSEC
8-K · Current reportMay 15, 2024ResultsSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
4 · Change in ownershipMay 8, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 8, 2024Insider tradeSEC
8-K · Current reportMay 6, 2024Management or board changeSEC
ARS · Annual report to shareholdersApr 18, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 18, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 18, 2024Meeting noticeSEC
4 · Change in ownershipApr 3, 2024Insider tradeSEC
4 · Change in ownershipApr 3, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 3, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 3, 2024Insider tradeSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
S-8 · Registration statement for employee plansMar 25, 2024Offer documentSEC
10-K · Annual reportMar 25, 2024Annual reportSEC
8-K · Current reportMar 25, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedMar 11, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 5, 2024Big-stake noticeSEC
8-K · Current reportFeb 2, 2024Management or board changeSEC
3 · Initial statement of ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
8-K · Current reportJan 30, 2024Current reportSEC
424B4 · ProspectusJan 26, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 26, 2024Other filingsSEC
8-K · Current reportJan 24, 2024ResultsSEC
S-1/A · Registration statement, amendedJan 24, 2024Offer documentSEC
CORRESP · Letter to the SECJan 23, 2024Other filingsSEC
CORRESP · Letter to the SECJan 23, 2024Other filingsSEC
S-1 · Registration statementJan 23, 2024Offer documentSEC
8-K · Current reportJan 22, 2024Current reportSEC
UPLOAD · Letter from the SECJan 16, 2024Other filingsSEC
DRS · Draft registration statementJan 10, 2024Offer documentSEC
8-K · Current reportDec 29, 2023Management or board changeSEC
4 · Change in ownershipDec 8, 2023Insider tradeSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
8-K · Current reportNov 21, 2023Management or board changeSEC
4 · Change in ownershipNov 20, 2023Insider tradeSEC
8-K · Current reportNov 13, 2023ResultsSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportOct 23, 2023Current reportSEC
8-K · Current reportSep 27, 2023Current reportSEC
SC 13G · Big-stake noticeSep 11, 2023Big-stake noticeSEC

This page holds 200 of 267 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Sagimet Biosciences Inc. - Series A’s releases

Common shares
70,341,169
Fully diluted
70,341,169

Fully diluted

LineShares
Common shares70,341,169

Share count over time

CountShares
Nov 22, 202670,341,169

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BlackRock6.97M9.9%US$68.9MSep 30, 2026
Balyasny Asset Management L.P.5.54M7.9%US$54.8MSep 30, 2026
Silverarc Capital Management, LLC3.75M5.3%US$37MSep 30, 2026
Vanguard3.59M5.1%US$35.4MSep 30, 2026
Bvf Inc3.5M5.0%US$34.6MSep 30, 2026
Woodline Partners LP3.14M4.5%US$31.1MSep 30, 2026
Federated Hermes, Inc.3.09M4.4%US$30.6MSep 30, 2026
Caligan Partners LP2.79M4.0%US$27.6MSep 30, 2026
Commodore Capital LP2.76M3.9%US$27.2MSep 30, 2026
Affinity Asset Advisors, LLC2.53M3.6%US$25MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
State Street2.43M3.5%US$24MSep 30, 2026
Saturn V Capital Management LP2M2.8%US$19.8MSep 30, 2026
Great Point Partners LLC1.96M2.8%US$19.4MSep 30, 2026
Ameriprise1.9M2.7%US$18.8MSep 30, 2026
Ra Capital Management, L.P.1.8M2.6%US$17.8MSep 30, 2026
Geode Capital1.54M2.2%US$15.3MSep 30, 2026
abrdn1.48M2.1%US$14.6MSep 30, 2026
Spruce Street Capital LP1.4M2.0%US$13.8MSep 30, 2026
Blue Owl Capital Holdings LP1.13M1.6%US$11.1MSep 30, 2026
Adage Capital Partners Gp, L.L.C.1.11M1.6%US$11MSep 30, 2026
D. E. Shaw & Co., Inc.1.04M1.5%US$10.3MSep 30, 2026
Marshall Wace, LLP752K1.1%US$7.43MSep 30, 2026
Driehaus Capital Management LLC727K1.0%US$7.18MSep 30, 2026
Atom Investors LP726K1.0%US$7.17MSep 30, 2026
Goldman Sachs569K0.81%US$5.62MSep 30, 2026
Dimensional527K0.75%US$5.21MSep 30, 2026
Boothbay Fund Management, LLC519K0.74%US$5.13MSep 30, 2026
J. Goldman & Co LP508K0.72%US$5.02MSep 30, 2026
Jones Hill Capital LP503K0.71%US$4.97MSep 30, 2026
Northern Trust482K0.69%US$4.77MSep 30, 2026
Nantahala Capital Management, LLC472K0.67%US$4.66MSep 30, 2026
UBS441K0.63%US$4.36MSep 30, 2026
Seven Fleet Capital Management LP429K0.61%US$4.24MSep 30, 2026
Superstring Capital Management LP423K0.60%US$4.18MSep 30, 2026
Millennium407K0.58%US$4.02MSep 30, 2026
Farallon Capital Management, L.L.C.400K0.57%US$3.95MSep 30, 2026
Morgan Stanley342K0.49%US$3.38MSep 30, 2026
Raymond James Financial Inc339K0.48%US$3.35MSep 30, 2026
Bank of America321K0.46%US$3.17MSep 30, 2026
Rock Springs Capital Management LP315K0.45%US$3.12MSep 30, 2026
Walleye Capital LLC308K0.44%US$3.04MSep 30, 2026
AWM Investment Company, Inc.300K0.43%US$2.96MSep 30, 2026
BNP Paribas258K0.37%US$2.55MSep 30, 2026
Palo Alto Investors LP250K0.36%US$2.47MSep 30, 2026
BNY211K0.30%US$2.08MSep 30, 2026
Wellington206K0.29%US$2.03MSep 30, 2026
Barclays202K0.29%US$2MSep 30, 2026
Acadian Asset Management LLC186K0.26%US$1.83MSep 30, 2026
Schwab176K0.25%US$1.74MSep 30, 2026
Invesco172K0.25%US$1.7MSep 30, 2026

This page holds 50 of 149 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Federated Hermes Kaufmann Small Cap Fund2.08M3.0%US$14.8MJul 31, 2026
Vanguard Total Stock Market Index Fund1.86M2.6%US$14.4MJun 30, 2026
iShares Russell 2000 ETF1.5M2.1%US$11.6MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF983K1.4%US$7.6MJun 30, 2026
Vanguard Extended Market Index Fund659K0.94%US$5.09MJun 30, 2026
Fidelity Small Cap Index Fund643K0.91%US$4.57MJul 31, 2026
BlackRock Health Sciences Opportunities Portfolio585K0.83%US$4.27MMay 29, 2026
iShares Russell 2000 Growth ETF432K0.61%US$3.34MJun 30, 2026
iShares Biotechnology ETF413K0.59%US$3.2MJun 30, 2026
Fidelity Extended Market Index Fund290K0.41%US$2.12MMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
iShares Micro-Cap ETF197K0.28%US$1.53MJun 30, 2026
Ultra-Small Company Fund166K0.24%US$1.29MJun 30, 2026
Schwab Small-Cap Index Fund143K0.20%US$1.02MJul 31, 2026
Dimensional U.S. Small Cap ETF137K0.19%US$972KJul 31, 2026
iShares Russell 2000 Value ETF119K0.17%US$918KJun 30, 2026
Master Small Cap Index Series110K0.16%US$849KJun 30, 2026
Fidelity Total Market Index Fund106K0.15%US$770KMay 31, 2026
U.S. Small Cap Portfolio102K0.14%US$724KJul 31, 2026
Fidelity Series Total Market Index Fund85,2720.12%US$622KMay 31, 2026
Nuveen Small Cap Blend Index Fund78,0770.11%US$555KJul 31, 2026
Avantis U.S. Small Cap Equity ETF73,0830.10%US$533KMay 31, 2026
U.S. Micro Cap Portfolio67,0350.10%US$477KJul 31, 2026
EQ/2000 Managed Volatility Portfolio63,6270.09%US$492KJun 30, 2026
Ultra-Small Company Market Fund48,9000.07%US$378KJun 30, 2026
Nuveen Equity Index Fund47,6830.07%US$339KJul 31, 2026
Fidelity Small Cap Growth Index Fund43,0600.06%US$333KJun 30, 2026
LVIP State Street Small-Cap Index Fund42,6000.06%US$329KJun 30, 2026
Health Sciences Portfolio34,9760.05%US$270KJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares33,4030.05%US$237KJul 31, 2026
Schwab Total Stock Market Index Fund33,0330.05%US$235KJul 31, 2026
Fidelity ZERO Total Market Index Fund32,7760.05%US$233KJul 31, 2026
Small Cap Index Fund30,3980.04%US$235KJun 30, 2026
Global X Russell 2000 ETF27,9510.04%US$199KJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund26,8560.04%US$208KJun 30, 2026
Goldman Sachs Absolute Return Tracker Fund23,3360.03%US$180KJun 30, 2026
Fidelity ZERO Extended Market Index Fund21,0620.03%US$150KJul 31, 2026
MetLife Russell 2000 Index Portfolio20,2250.03%US$156KJun 30, 2026
Vanguard Balanced Index Fund19,4170.03%US$150KJun 30, 2026
Fidelity Nasdaq Composite Index Fund18,5710.03%US$135KMay 31, 2026
Fidelity Small Cap Value Index Fund17,9840.03%US$139KJun 30, 2026
Small-Cap Index Portfolio16,7930.02%US$130KJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio15,1000.02%US$117KJun 30, 2026
1290 VT Micro Cap Portfolio13,1750.02%US$102KJun 30, 2026
ATM Small Cap Managed Volatility Portfolio13,0490.02%US$101KJun 30, 2026
NVIT Small Cap Index Fund12,9620.02%US$100KJun 30, 2026
Small Cap Index Trust12,0990.02%US$93,525Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund10,4220.01%US$74,100Jul 31, 2026
Biotechnology Ultrasector Profund9,3730.01%US$66,642Jul 31, 2026
DWS Small Cap Index VIP9,2200.01%US$71,271Jun 30, 2026
EQ/Small Company Index Portfolio9,1000.01%US$70,343Jun 30, 2026

This page holds 50 of 103 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Kemble George
Director
Sale350,987USD 10.23US$3.59MAug 14, 2026
Kemble George
Director
Sale20,206USD 9.95US$201KAug 11, 2026
Kemble George
Director
Sale18,844USD 7.46US$141KJul 20, 2026
Rozek Elizabeth
Officer: Chief Legal & Admin. Officer
Sale10,545USD 7.76US$81,829Jul 20, 2026
Happel David
Director, Officer: President & CEO
Sale64,051USD 7.76US$497KJul 20, 2026

Big stakes

StakeStakeSharesDateFiling
Balyasny Asset Management L.P.9.00%5.54MSep 30, 2026Schedule 13G
BlackRock, Inc.7.80%4.75MJun 30, 2026Schedule 13G
Commodore Capital LP7.60%5.51MSep 30, 2026Schedule 13G
Silverarc Capital Management, LLC6.10%3.75MSep 30, 2026Schedule 13G
Woodline Partners LP5.10%3.14MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Timothy P. Walbert
Other companies: Latigo Biotherapeutics, Inc. (Chair, Board of Directors · Since at least Aug 6, 2026); Kardigan, Inc. (Board of Directors · Since at least Jun 17, 2026); Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); BioMarin Pharmaceutical Inc. (Director · Since at least Feb 24, 2025); Mirum Pharmaceuticals, Inc. (Director · Since at least Apr 5, 2023); Century Therapeutics, Inc. (Director · Since at least Oct 1, 2022); Aurinia Pharmaceuticals Inc (Director · Jan 1, 2021 – May 18, 2022 · Past); Assertio Holdings, Inc. (Director · May 20, 2020 – May 20, 2020 · Past); Exicure, Inc. (Director · Jul 22, 2019 – Jun 2, 2021 · Past); Sucampo Pharmaceuticals Inc (Director · Oct 12, 2015 – Feb 13, 2018 · Past); Egalet Corporation (Director · Mar 10, 2014 – May 20, 2020 · Past); Horizon Pharma PLC (Chairman, President and CEO, Director · Jul 28, 2011 – Mar 23, 2019 · Past); Raptor Pharmaceutical Corp (Director · Apr 11, 2011 – Mar 13, 2014 · Past); Idm Pharma Inc (President and CEO, Director · May 25, 2007 – Apr 3, 2008 · Past)
Director · Since at least Apr 1, 2024
Beth C Seidenberg
Other companies: Latigo Biotherapeutics, Inc. (Director · Since at least Aug 6, 2026); Kyverna Therapeutics, Inc. (Director · Since at least Feb 7, 2024); Vera Therapeutics, Inc. (Director · Since at least May 13, 2021); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Progyny, Inc. (Director · Oct 24, 2019 – May 23, 2024 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); Atara Biotherapeutics, Inc. (Director · Oct 15, 2014 – May 31, 2023 · Past); Epizyme Inc (Director · May 30, 2013 – Jun 30, 2019 · Past); Tesaro Inc (Director · Jun 27, 2012 – Jan 22, 2019 · Past)
Director · Since at least Jul 13, 2023
Jennifer Jarrett
Other companies: Damora Therapeutics, Inc. (President and Chief Executive Officer in March 2026, Board Director · Since at least Mar 30, 2026); Zura Bio Limited (Director · Since at least Mar 20, 2023); Syndax Pharmaceuticals, Inc. (Director · Since at least Sep 25, 2018); Arcus Biosciences, Inc. (Chief Operating Officer · Since at least Mar 14, 2018); Radius Health, Inc. (Director · May 18, 2022 – Aug 15, 2022 · Past); Surrozen, Inc. (Director · Nov 18, 2020 – Nov 18, 2020 · Past); Arena Pharmaceuticals Inc (Director · Jun 13, 2017 – Mar 11, 2022 · Past); Audentes Therapeutics Inc (Director · Jun 12, 2017 – Jan 15, 2020 · Past); Medivation Inc (Chief Financial Officer · Apr 7, 2016 – Sep 28, 2016 · Past)
Board Member · Since at least Aug 1, 2024
Richard Rodgers
Other companies: Novavax, Inc. (Director · Since at least Oct 29, 2022); Opus Genetics, Inc. (Director · Since at least Dec 2, 2014); Ardelyx, Inc. (Director · Since at least Jun 18, 2014); Tesaro Inc (Executive VP & CFO · Jun 27, 2012 – Mar 6, 2013 · Past); Abraxis BioScience Inc (Senior Vice President and CFO · Jul 9, 2009 – Jul 13, 2009 · Past); Mgi Pharma Inc (Sr. VP and Controller · Jul 15, 2006 – Jan 28, 2008 · Past)
Director · Jul 13, 2023 – Jul 18, 2023 · Past
Anne Phillips
Other companies: vTv Therapeutics Inc. (Director · Since at least Mar 13, 2024); Trevena, Inc. (Member of Nominating and Corporate Governance Committee · Since at least Dec 16, 2014); Vaccitech plc (Director · Apr 29, 2021 – May 11, 2023 · Past); AMAG Pharmaceuticals Inc (Director · Apr 10, 2019 – Nov 16, 2020 · Past)
Board Member · Since at least Aug 1, 2024
Merdad Parsey
Other companies: Ardelyx, Inc. (Director · Since at least Apr 28, 2025); ArriVent BioPharma, Inc. (Director · Since at least Apr 28, 2025); Arcus Biosciences, Inc. (Director · Jul 13, 2020 – Jul 13, 2020 · Past); Gilead Sciences, Inc. (Chief Medical Officer · Nov 1, 2019 – Dec 10, 2024 · Past)
Director · Jul 13, 2023 – Jun 5, 2024 · Past
Beth Seidenberg
Other companies: Vera Therapeutics, Inc. (Founding Managing Director, Westlake Village BioPartners · Since at least Nov 4, 2026); Latigo Biotherapeutics, Inc. (Founding Managing Director, Westlake BioPartners · Since at least Aug 10, 2026); Kyverna Therapeutics, Inc. (Independent Director · Since at least May 29, 2026)
Lead Independent Director · Since at least Nov 4, 2026
Dennis Hom
Other companies: ProQR Therapeutics N.V. (Chief Financial Officer · Since at least Apr 14, 2025); Achaogen Inc (VP, Finance and Corp. Dev. · Mar 11, 2014 – Mar 11, 2014 · Past)
Chief Financial Officer · Jul 13, 2023 – Jul 18, 2023 · Past
Andreas Grauer
Other companies: Corcept Therapeutics Incorporated (Chief Medical Officer · Mar 18, 2019 – Feb 5, 2021 · Past)
Chief Medical Officer · Since at least Apr 20, 2026
Elizabeth Grammer
Other companies: Ardelyx, Inc. (See Remarks · Since at least Jun 18, 2014)
Board Member · Since at least Jul 13, 2023
All 21 people
PersonSeat
Thierry Chauche
Other companies: Provention Bio Inc (Chief Financial Officer · Dec 1, 2021 – Apr 27, 2023 · Past)
Chief Financial Officer · Since at least May 6, 2024
Anthony M RimacChief Operating Officer · Jul 13, 2023 – Jul 18, 2023 · Past
David HappelChief Executive Officer & Director · Since at least Nov 16, 2023
Eduardo Bruno MartinsChief Medical Officer · Since at least Jul 13, 2023
Elizabeth RozekChief Legal & Administrative Officer · Since at least Nov 17, 2023
George KembleChair · Since at least Jul 13, 2023
Jinzi Jason WuDirector · Jul 13, 2023 – Jul 18, 2023 · Past
Joseph OritiSee Remarks · Feb 1, 2024 – Feb 1, 2024 · Past
Marie O’FarrellChief Scientific Officer · Since at least Jan 6, 2025
Paul HoelscherBoard Member · Since at least Apr 1, 2024
Robert D’UrsoSenior Vice President of New Products · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Sagimet Biosciences Inc. - Series A.